期刊
JOURNAL OF THORACIC ONCOLOGY
卷 16, 期 2, 页码 318-326出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtho.2020.09.007
关键词
Immune-related adverse events; Immune checkpoint inhibitor-related hepatitis; Immune checkpoint inhibitor-related cholangitis; Anti-IL-6 therapy
资金
- Leenaards Foundation
The study found that targeted therapy focusing on T cells, such as using the IL-6 receptor-neutralizing antibody tocilizumab, can effectively alleviate the severity of the disease in patients with CS-refractory irCH, showing promising therapeutic potential. However, further validation in a larger patient population is necessary.
Introduction: For patients with corticosteroid (CS)-refractory immune checkpoint inhibitor-related cholangiohepatitis (irCH), no consensus exists regarding treatment, and outcomes remain poor. We evaluated the possibility of personalized treatment according to the patient's cytokine profile and the immunohistopathologic assessment of the predominant immune infiltrate type of liver tissue. Methods: NSCLCs with CS-refractory irCH were analyzed by immunohistochemistry of liver biopsy specimen, serum cytokine panel, and assessment of peripheral blood mononuclear cell immune cell monitoring by mass cytometry. Results: A total of three consecutive patients with irCH were identified. We found a predominant T-cell infiltrate and an interferon-gamma or T helper 1 proinflammatory cytokine profile. Here, we report for the first time that a T-cell-targeted therapy with the interleukin (IL)-6 receptor-neutralizing antibody tocilizumab, which inhibits signaling downstream of interferon-gamma and several other Janus kinase-dependent cytokines, is an effective single cytokine-directed therapy for CS-refractory irCH. Three patients with severe, CS-refractory irCH who were treated with tocilizumab were found to have persistent clinical and biological remission. Conclusions: Dysregulation of the IL-6/T-cell axis may contribute to the pathogenesis of CS-refractory irCH. Our observations suggest that IL-6 blockade seems to have promise in the treatment of CS-refractory irCH. The results from our three patients need to be confirmed in a larger patient population. (C) 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据